Sodium dihydrogen phosphate (MSP)

Sodium dihydrogen phosphate (NaH2PO4), also known as monosodium phosphate, is an inorganic salt that serves as a source of phosphorus and a pH buffering agent. It is not a therapeutic target in the traditional sense, such as a receptor or enzyme, but is instead a chemical compound used as a medication or dietary supplement (PubChem CID 23666111). Clinically, it is frequently employed as an osmotic laxative for bowel preparation prior to colonoscopy or surgery, and as a treatment for hypophosphatemia (StatPearls, 2023). The compound works by increasing the osmotic pressure in the intestine to promote bowel movements or by providing phosphate ions necessary for ATP production and bone health (NIH MedlinePlus). In the context of chronic kidney disease, the phosphate ion provided by this salt is a key physiological parameter targeted by phosphate-binding drugs like sevelamer to prevent hyperphosphatemia (FDA, 2014). However, its use requires careful monitoring due to risks of electrolyte disturbances and potential kidney injury known as acute phosphate nephropathy. Overall, while it is a vital physiological component, it is classified as a pharmaceutical substance rather than a biological target for drug discovery.

Other names

Monosodium phosphateMonobasic sodium phosphateSodium phosphate monobasicSodium acid phosphateNaH2PO4

As a drug, it acts as an osmotic laxative or phosphate supplement; as a molecule, it is targeted by phosphate binders which sequester the phosphate ion in the gastrointestinal tract to prevent absorption.